Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17568) 17568
Publication (1616) 1616
Newsletter (1074) 1074
Newspaper Article (444) 444
Book Review (385) 385
Book Chapter (194) 194
Magazine Article (72) 72
Book / eBook (58) 58
Transcript (40) 40
Conference Proceeding (19) 19
Dissertation (16) 16
Reference (8) 8
Web Resource (5) 5
Data Set (4) 4
Paper (3) 3
Trade Publication Article (3) 3
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9919) 9919
humans (9695) 9695
animals (7487) 7487
male (6918) 6918
fatty acids (4681) 4681
female (4421) 4421
fatty liver (3640) 3640
mice (3443) 3443
liver (3371) 3371
metabolism (3156) 3156
obesity (2981) 2981
insulin resistance (2932) 2932
research (2926) 2926
rats (2755) 2755
lipids (2659) 2659
middle aged (2629) 2629
liver - metabolism (2596) 2596
insulin-resistance (2432) 2432
adult (2338) 2338
liver diseases (2333) 2333
inflammation (2227) 2227
rodents (2209) 2209
diabetes (2197) 2197
liver - drug effects (2164) 2164
oxidative stress (2023) 2023
diet (2021) 2021
health aspects (1996) 1996
physiological aspects (1995) 1995
risk factors (1898) 1898
medicine (1868) 1868
gastroenterology & hepatology (1831) 1831
metabolic syndrome (1791) 1791
endocrinology & metabolism (1785) 1785
fatty liver - drug therapy (1738) 1738
cholesterol (1727) 1727
fatty liver-disease (1723) 1723
care and treatment (1689) 1689
pharmacology & pharmacy (1685) 1685
research article (1679) 1679
nutrition & dietetics (1668) 1668
insulin (1639) 1639
glucose (1624) 1624
proteins (1620) 1620
biochemistry & molecular biology (1589) 1589
gene expression (1588) 1588
liver - pathology (1582) 1582
analysis (1445) 1445
multidisciplinary sciences (1395) 1395
mice, inbred c57bl (1393) 1393
disease (1326) 1326
aged (1316) 1316
steatosis (1305) 1305
lipid metabolism (1295) 1295
disease models, animal (1286) 1286
cancer (1285) 1285
non-alcoholic fatty liver disease (1284) 1284
review (1270) 1270
type 2 diabetes (1264) 1264
science (1203) 1203
nonalcoholic steatohepatitis (1181) 1181
article (1180) 1180
medical research (1177) 1177
expression (1149) 1149
studies (1122) 1122
hepatic steatosis (1075) 1075
enzymes (1061) 1061
fibrosis (1059) 1059
apoptosis (1054) 1054
triglycerides (1053) 1053
treatment outcome (1039) 1039
physiology (1031) 1031
medicine, research & experimental (1028) 1028
dietary supplements (1003) 1003
fatty liver - metabolism (975) 975
triglycerides - blood (961) 961
diabetes mellitus (956) 956
biology (948) 948
fatty liver - pathology (935) 935
non-alcoholic fatty liver disease - drug therapy (929) 929
cell biology (916) 916
kinases (902) 902
drug therapy (877) 877
steatohepatitis (863) 863
medicine, experimental (862) 862
gene-expression (847) 847
metabolic disorders (840) 840
nutrition (839) 839
lipid metabolism - drug effects (833) 833
rats, sprague-dawley (821) 821
homeostasis (819) 819
body weight (805) 805
blood glucose - metabolism (803) 803
fatty acids - metabolism (800) 800
adipose-tissue (796) 796
development and progression (793) 793
signal transduction (793) 793
metabolites (782) 782
biochemistry (780) 780
antioxidants (779) 779
oncology (772) 772
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (35) 35
UofT at Mississauga - Stacks (5) 5
Engineering & Comp. Sci. - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Royal Ontario Museum - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18649) 18649
German (163) 163
Chinese (154) 154
Russian (126) 126
French (86) 86
Japanese (58) 58
Italian (52) 52
Spanish (50) 50
Hungarian (21) 21
Korean (21) 21
Ukrainian (17) 17
Polish (15) 15
Czech (13) 13
Dutch (8) 8
Slovak (5) 5
Portuguese (4) 4
Croatian (3) 3
Danish (3) 3
Swedish (3) 3
Bulgarian (2) 2
Hebrew (2) 2
Romanian (2) 2
Turkish (2) 2
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text A Liver Full of JNK: Signaling in Regulation of Cell Function and Disease Pathogenesis, and Clinical Approaches
by Seki, Ekihiro and Brenner, David A and Karin, Michael
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 2, pp. 307 - 320
c-Jun-N-terminal kinase (JNK) is a mitogen-activated protein kinase family member that is activated by diverse stimuli, including cytokines (such as tumor... 
Gastroenterology and Hepatology | c-Jun | MAPK | Acetaminophen | TNF | Insulin Resistance | Hepatocellular Carcinoma | N-TERMINAL KINASE | JUN NH2-TERMINAL KINASE | ENDOPLASMIC-RETICULUM STRESS | TNF-INDUCED APOPTOSIS | KAPPA-B | MITOCHONDRIAL PERMEABILITY TRANSITION | HEPATOCYTE SURVIVAL | INSULIN-RESISTANCE | COMPENSATORY PROLIFERATION | GASTROENTEROLOGY & HEPATOLOGY | Acetaminophen - adverse effects | Liver Transplantation | Humans | JNK Mitogen-Activated Protein Kinases - metabolism | Metabolic Syndrome - metabolism | Liver - physiopathology | Metabolic Syndrome - drug therapy | MAP Kinase Signaling System | Carcinoma, Hepatocellular - drug therapy | Analgesics, Non-Narcotic - adverse effects | Cell Death | Biomarkers - metabolism | Liver Regeneration | Fatty Liver - metabolism | JNK Mitogen-Activated Protein Kinases - antagonists & inhibitors | Liver - metabolism | Liver Neoplasms - drug therapy | Fatty Liver - drug therapy | Animals | Chemical and Drug Induced Liver Injury - metabolism | Protein Kinase Inhibitors - therapeutic use | Chemical and Drug Induced Liver Injury - drug therapy | JNK Mitogen-Activated Protein Kinases - physiology | Liver Neoplasms - metabolism | Liver - physiology | Liver Diseases - drug therapy | Mice | Primary Graft Dysfunction - metabolism | Liver Diseases - physiopathology | Liver Diseases - metabolism | Carcinoma, Hepatocellular - metabolism | Enzymes | Medical colleges | Platelet-derived growth factor | Liver diseases | Isoenzymes | Genes | Liver | Development and progression | Transforming growth factors | Fatty acids | Liver cancer | Epidermal growth factor | Interleukins | DNA | Genetically modified organisms | Physiological aspects | Insulin resistance | Tumor proteins | Mitogens | Protein kinases | Tumors | Index Medicus | Abridged Index Medicus | acetaminophen | insulin resistance | hepatocellular carcinoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury
by Baeck, Christer and Wehr, Alexander and Karlmark, Karlin Raja and Heymann, Felix and Vucur, Mihael and Gassler, Nikolaus and Huss, Sebastian and Klussmann, Sven and Eulberg, Dirk and Luedde, Tom and Trautwein, Christian and Tacke, Frank
Gut, ISSN 0017-5749, 03/2012, Volume 61, Issue 3, pp. 416 - 426
ObjectiveMonocyte chemoattractant protein-1 (MCP-1, CCL2), the primary ligand for chemokine receptor C–C chemokine receptor 2 (CCR2), is increased in livers of... 
FIBROSIS | STEATOSIS | INSULIN-RESISTANCE | INFLAMMATION | BONE-MARROW | DISEASE | MONOCYTE SUBSETS | MICE | SPIEGELMER | GASTROENTEROLOGY & HEPATOLOGY | CCR2 | Liver - pathology | Carbon Tetrachloride | Liver Cirrhosis, Experimental - etiology | Bone Marrow Cells - physiology | Male | Chemical and Drug Induced Liver Injury, Chronic - drug therapy | Liver Cirrhosis, Experimental - prevention & control | Non-alcoholic Fatty Liver Disease | Chemokine CCL2 - physiology | Bone Marrow Cells - drug effects | Chemical and Drug Induced Liver Injury - pathology | Chemical and Drug Induced Liver Injury, Chronic - complications | Macrophages - physiology | Aptamers, Nucleotide - pharmacology | Drug Evaluation, Preclinical - methods | Acute Disease | Cytokines - metabolism | Liver - metabolism | Mice, Inbred C57BL | Cells, Cultured | Fatty Liver - prevention & control | Aptamers, Nucleotide - therapeutic use | Chemotaxis - drug effects | Chemical and Drug Induced Liver Injury, Chronic - pathology | Disease Progression | Fatty Liver - drug therapy | Animals | Chemical and Drug Induced Liver Injury - complications | Chemical and Drug Induced Liver Injury - drug therapy | Macrophages - drug effects | Mice | Chemokine CCL2 - antagonists & inhibitors | Fatty Liver - etiology | Care and treatment | Liver diseases | Fibrosis | Models | Research | Macrophages | Chemokine receptors | Studies | Cytokines | Polyethylene glycol | Rodents | Liver | Clinical trials | Tumor necrosis factor-TNF | Inflammation | Diabetes | Metabolic disorders | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
by Belfort, Renata and Harrison, Stephen A and Brown, Kenneth and Darland, Celia and Finch, Joan and Hardies, Jean and Balas, Bogdan and Gastaldelli, Amalia and Tio, Fermin and Pulcini, Joseph and Berria, Rachele and Ma, Jennie Z and Dwivedi, Sunil and Havranek, Russell and Fincke, Chris and DeFronzo, Ralph and Bannayan, George A and Schenker, Steven and Cusi, Kenneth
The New England Journal of Medicine, ISSN 0028-4793, 11/2006, Volume 355, Issue 22, pp. 2297 - 2307
In this placebo-controlled, randomized trial of pioglitazone in subjects with nonalcoholic steatohepatitis, pioglitazone was associated with improvements in... 
RAT-LIVER | MEDICINE, GENERAL & INTERNAL | VITAMIN-E | ACTIVATED PROTEIN-KINASE | TYPE-2 DIABETIC-PATIENTS | PLASMA ADIPONECTIN | OBESE SUBJECTS | HEPATIC INSULIN-RESISTANCE | FATTY LIVER-DISEASE | WEIGHT-LOSS | ADIPOSE-TISSUE | Liver - pathology | Caloric Restriction | Fatty Liver - pathology | Humans | Middle Aged | Fatty Liver - complications | Diabetes Mellitus, Type 2 - diet therapy | Male | Insulin - blood | Necrosis | Hepatitis - drug therapy | Glucose Intolerance - drug therapy | Thiazolidinediones - therapeutic use | Female | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Fatty Liver - diet therapy | Double-Blind Method | Insulin Resistance | Combined Modality Therapy | Fatty Liver - drug therapy | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Liver Cirrhosis - pathology | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hepatitis - diet therapy | Hepatitis | Care and treatment | Drug therapy | Fibrosis | Insulin resistance | Diabetes | Glucose | Diet | Kinases | Insulin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
by Athyros, Vasilios G, MD and Tziomalos, Konstantinos, MD and Gossios, Thomas D, MD and Griva, Theodora, MD and Anagnostis, Panagiotis, MD and Kargiotis, Konstantinos, MD and Pagourelias, Efstathios D, MD and Theocharidou, Eleni, MD and Karagiannis, Asterios, Prof and Mikhailidis, Dimitri P, Dr and GREACE Study Collaborative Grp and GREACE Study Collaborative Group
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9756, pp. 1916 - 1922
Summary Background Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | NONALCOHOLIC FATTY LIVER | METABOLIC SYNDROME | CHOLESTEROL | TRANSAMINASE | GAMMA-GLUTAMYL-TRANSFERASE | RENAL-FUNCTION | FOLLOW-UP | UNTREATED DYSLIPIDEMIA | SUBGROUP ANALYSIS | URIC-ACID LEVELS | Liver Function Tests | Recurrence | Prospective Studies | Risk Reduction Behavior | Fatty Liver - blood | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Fatty Liver - complications | Male | Treatment Outcome | Fatty Liver - drug therapy | Greece | Time Factors | Coronary Disease - complications | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Non-alcoholic Fatty Liver Disease | Coronary Disease - drug therapy | Female | Aged | Dosage and administration | Drug therapy | Coronary heart disease | Patient outcomes | Statins | Heart failure | Hospitals | Mortality | Atherosclerosis | Data collection | Cardiovascular disease | Insulin resistance | Diabetes | Regression analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies
by Sunny, Nishanth E and Bril, Fernando and Cusi, Kenneth
Trends in Endocrinology & Metabolism, ISSN 1043-2760, 2016, Volume 28, Issue 4, pp. 250 - 260
Nonalcoholic fatty liver disease (NAFLD) is prevalent in patients with obesity or type 2 diabetes. Nonalcoholic steatohepatitis (NASH), encompassing steatosis... 
Endocrinology & Metabolism | nonalcoholic steatohepatitis | pioglitazone | mitochondria | glucagon-like peptide-1 | fatty liver | diabetes | obesity | DIABETES-MELLITUS | SKELETAL-MUSCLE | VITAMIN-E | TCA CYCLE | LIFE-STYLE | HEPATIC INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | WEIGHT-LOSS | 1-C-13 ACETATE | RANDOMIZED CONTROLLED-TRIAL | OBESE INDIVIDUALS | Non-alcoholic Fatty Liver Disease - pathology | Fatty Liver - metabolism | Glucagon-Like Peptide 1 - metabolism | Obesity - drug therapy | Fatty Liver - pathology | Humans | Non-alcoholic Fatty Liver Disease - therapy | Fatty Liver - therapy | Mitochondria - metabolism | Non-alcoholic Fatty Liver Disease - metabolism | Mitochondria - pathology | Fatty Liver - drug therapy | Non-alcoholic Fatty Liver Disease - drug therapy | Obesity - metabolism | Obesity - pathology | Thiazolidinediones - therapeutic use | Animals | Obesity - therapy | Type 2 diabetes | Physiological aspects | Fatty liver | Liver cirrhosis | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial
by Lavine, Joel E and Schwimmer, Jeffrey B and Van Natta, Mark L and Molleston, Jean P and Murray, Karen F and Rosenthal, Philip and Abrams, Stephanie H and Scheimann, Ann O and Sanyal, Arun J and Chalasani, Naga and Tonascia, James and Ünalp, Aynur and Clark, Jeanne M and Brunt, Elizabeth M and Kleiner, David E and Hoofnagle, Jay H and Robuck, Patricia R and Nonalcoholic Steatohepatitis Clinical Research Network, for the and Nonalcoholic Steatohepatitis Clini and Nonalcoholic Steatohepatitis Clinical Research Network
JAMA, ISSN 0098-7484, 04/2011, Volume 305, Issue 16, pp. 1659 - 1668
CONTEXT Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in US children and adolescents and can present with advanced fibrosis... 
MEDICINE, GENERAL & INTERNAL | STEATOHEPATITIS | THERAPY | HISTOPATHOLOGY | Hypoglycemic Agents - therapeutic use | Severity of Illness Index | Obesity | Metformin - therapeutic use | Double-Blind Method | Humans | Male | Treatment Outcome | Alanine Transaminase - blood | Fatty Liver - drug therapy | Antioxidants - therapeutic use | Adolescent | Fatty Liver - enzymology | Non-alcoholic Fatty Liver Disease | Vitamin E - therapeutic use | Female | Child | Clinical trials | Teenagers | Liver diseases | Vitamin E | Children & youth
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
by Perry, Rachel J and Samuel, Varman T and Petersen, Kitt F and Shulman, Gerald I
Nature, ISSN 0028-0836, 2014, Volume 510, Issue 7503, pp. 84 - 91
Non-alcoholic fatty liver disease and its downstream sequelae, hepatic insulin resistance and type 2 diabetes, are rapidly growing epidemics, which lead to... 
SKELETAL-MUSCLE | NONALCOHOLIC FATTY LIVER | METABOLIC SYNDROME | ENERGY-EXPENDITURE | WEIGHT-REDUCTION | DE-NOVO LIPOGENESIS | PYRUVATE-CARBOXYLASE | CGI-58 KNOCKDOWN | MULTIDISCIPLINARY SCIENCES | CELLULAR MECHANISMS | C3 GENE VARIANTS | Fatty Liver - metabolism | Triglycerides - biosynthesis | Humans | Liver - metabolism | Insulin Resistance | Lipid Metabolism | Muscle, Skeletal - metabolism | Lipodystrophy - metabolism | Diabetes Mellitus, Type 2 - metabolism | Lipids - biosynthesis | Fatty Liver - drug therapy | Hyperglycemia - metabolism | Animals | Diglycerides - metabolism | Non-alcoholic Fatty Liver Disease | Diabetes Mellitus, Type 2 - drug therapy | Lipogenesis | Type 2 diabetes | Physiological aspects | Insulin resistance | Lipids | Fatty liver | Obesity | Weight control | Rodents | Diabetes | Kinases | Insulin | Liver cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial
by Sanyal, Arun J and Abdelmalek, Manal F and Suzuki, Ayako and Cummings, Oscar W and Chojkier, Mario and EPE-A Study Grp and EPE-A Study Group
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 377 - 384.e1
Background & Aims n-3 polyunsaturated fatty acids reduce insulin resistance, lipogenesis, and inflammation, which are features of nonalcoholic steatohepatitis... 
Gastroenterology and Hepatology | Metabolic Syndrome | Triglycerides | Ethyl All-Cis-5,8,11,14,17-Eicosapentaenoate | UNITED-STATES | POPULATION | FATTY LIVER-DISEASE | N-3 | INSULIN-RESISTANCE | CIRRHOSIS | TERM-FOLLOW-UP | OUTCOMES | GASTROENTEROLOGY & HEPATOLOGY | HEPATIC STEATOSIS | ASSOCIATION | Severity of Illness Index | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Liver - pathology | Prospective Studies | Double-Blind Method | Fatty Liver - pathology | Eicosapentaenoic Acid - analogs & derivatives | Humans | Middle Aged | Eicosapentaenoic Acid - adverse effects | Fatty Liver - complications | Male | North America | Disease Progression | Fatty Liver - drug therapy | Liver - drug effects | Time Factors | Biopsy | Treatment Failure | Non-alcoholic Fatty Liver Disease | Liver Cirrhosis - pathology | Female | Eicosapentaenoic Acid - therapeutic use | Clinical trials | Unsaturated fatty acids | Insulin resistance | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
by Ratziu, Vlad and Charlotte, Fréderic and Bernhardt, Carole and Giral, Philippe and Halbron, Marine and LeNaour, Gilles and Hartmann‐Heurtier, Agnès and Bruckert, Eric and Poynard, Thierry and LIDO Study Grp and LIDO Study Group
Hepatology, ISSN 0270-9139, 02/2010, Volume 51, Issue 2, pp. 445 - 453
Short‐term trials of glitazones in nonalcoholic steatohepatitis (NASH) yielded controversial histological results. Longer treatment might result in additional... 
FIBROSIS | HEPATIC STELLATE CELLS | PIOGLITAZONE | MONOTHERAPY | CARDIOVASCULAR OUTCOMES | DISEASE | GAMMA LIGAND | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | TYPE-2 DIABETES-MELLITUS | THIAZOLIDINEDIONES | Hypoglycemic Agents - therapeutic use | Liver Cirrhosis - drug therapy | Double-Blind Method | Fatty Liver - pathology | Liver Cirrhosis - complications | Humans | Middle Aged | Fatty Liver - complications | Male | Fatty Liver - drug therapy | Thiazolidinediones - therapeutic use | Time Factors | Liver Cirrhosis - pathology | Female
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights